All In Biotech

Drug Trial Radar · NCT07918859

A Study of Imlunestrant (LY3484356) in Healthy Female Participants

A Phase 1, Open-Label, 4-Part Study to Investigate the Relative Bioavailability and Bioequivalence of Imlunestrant (LY3484356) Test and Reference Formulations and the Effects of Food and Omeprazole on the Pharmacokinetics of Imlunestrant, in Healthy Female Participants of Non-Childbearing Potential

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 343 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

343

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Nov 5, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to measure the amount of imlunestrant that gets into the bloodstream and how long it takes the body to get rid of it when given in two different formulations. This study also compares the two different formulations of imlunestrant against the effects of food and omeprazole in the body. For each participant, the study may last up to 2.5 months and participants can expect to stay in the clinical research unit (CRU) up to 27 days over several visits.

Conditions

  • Healthy

Interventions

  • Imlunestrant (Test)Drug

    Administered orally

  • Imlunestrant (Reference)Drug

    Administered orally

  • OmeprazoleDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Imlunestrant (Freebase)Time frame: Baseline, Up to Day 36
  2. 2. PK: Area Under the Concentration Versus Time Curve (AUC) of Imlunestrant (Freebase)Time frame: Baseline, Up to Day 36

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Qps-Mra, Llc

    South Miami, Florida

  • ICON

    Lenexa, Kansas

  • QPS Missouri

    Springfield, Missouri

  • ICON Early Phase Services

    San Antonio, Texas

  • ICON

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.